We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Lab Evidence Confirms Outbreak of Haff Disease

By LabMedica International staff writers
Posted on 28 Jun 2017
Print article
Image: The ABI-Prism 3500 genetic analyzer (Photo courtesy of Applied Biosystems).
Image: The ABI-Prism 3500 genetic analyzer (Photo courtesy of Applied Biosystems).
Haff disease is a syndrome of unexplained rhabdomyolysis following consumption of certain types of fish, and it is caused by an unidentified toxin. Rhabdomyolysis is a clinical syndrome caused by injury to skeletal muscle that results in release of muscle cell contents into the circulation.

Cases of Haff disease were first described in 1924, in the Baltic region of Prussia and Sweden and involved the consumption of different cooked freshwater fish, such as burbot, pike and freshwater eel. In the USA, the first cases of Haff disease were reported in Texas in 1984, and six additional cases of Haff disease were reported in patients from California and Missouri, who had eaten buffalo fish.

A team of Brazilian scientists led by those at the Faculdade de Tecnologia e Ciencias Medical School (Salvador, Brazil) have presented data on an a series of 15 Haff disease cases from an outbreak in Salvador, Brazil, starting early December 2016. Eleven cases were grouped in four family clusters of two to four individuals, and four were isolated cases. The investigators reported that all but one of the patient consumed cooked fish; 11 within 24 hours before symptoms onset. Cases consumed ‘Olho de Boi’ (Seriola spp.) and ’Badejo’ (Mycteroperca spp.). A total of 67 cases were detected, the last case was reported on April 5, 2017.

The scientists performed serial measurements of muscle enzymes, such as creatine phosphokinase (CPK), aspartate aminotransferase (AST), alanine aminotransferase (ALT) and lactate dehydrogenase (LDH) in all patients. In addition, troponin I levels and creatine kinase-MB (CK-MB) fractions were measured in three and two cases, respectively. They screened 10 patients for chikungunya and Zika virus RNA. Sequencing was performed by a sequencing facility using the ABI-Prism 3500 genetic analyzer.

The team found that CPK levels at presentation ranged from 743 to 105,755 U/L, which was extremely elevated, and decreased rapidly on subsequent days in parallel with the improvement of symptoms. Troponin I levels were less than 0.034 ng/mL in all patients with measurements. CK-MB fraction ranged from 1.9% to 6.3%. Reverse transcription polymerase chain reaction (RT-PCR) for chikungunya and Zika viruses, as well as nested RT-PCR for parechovirus, yielded negative results for all patients in all types of samples. The RT-PCR for enterovirus generated non-specific products in four samples. However, upon analysis of the sequenced fragments no virus could be identified.

The authors concluded that it is important for travel medicine physicians to be alert in case of patients returning from Salvador, Brazil, with myalgia and symptoms of rhabdomyolysis to consider Haff disease as a possible differential diagnosis. Care should also be taken when treating these patients so as to avoid non-steroidal anti-inflammatory agents because of possible concurrent renal toxicity. The study was published on June 15, 2017, in the journal Eurosurveillance.

Related Links:
Faculdade de Tecnologia e Ciencias Medical School

Gold Member
Flocked Fiber Swabs
Puritan® Patented HydraFlock®
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Troponin I Test
Quidel Triage Troponin I Test
New
Piezoelectric Micropump
Disc Pump

Print article

Channels

Molecular Diagnostics

view channel
Image: The Mirvie RNA platform predicts pregnancy complications months before they occur using a simple blood test (Photo courtesy of Mirvie)

RNA-Based Blood Test Detects Preeclampsia Risk Months Before Symptoms

Preeclampsia remains a major cause of maternal morbidity and mortality, as well as preterm births. Despite current guidelines that aim to identify pregnant women at increased risk of preeclampsia using... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Microbiology

view channel
Image: The lab-in-tube assay could improve TB diagnoses in rural or resource-limited areas (Photo courtesy of Kenny Lass/Tulane University)

Handheld Device Deliver Low-Cost TB Results in Less Than One Hour

Tuberculosis (TB) remains the deadliest infectious disease globally, affecting an estimated 10 million people annually. In 2021, about 4.2 million TB cases went undiagnosed or unreported, mainly due to... Read more

Technology

view channel
Image: Schematic illustration of the chip (Photo courtesy of Biosensors and Bioelectronics, DOI: https://doi.org/10.1016/j.bios.2025.117401)

Pain-On-A-Chip Microfluidic Device Determines Types of Chronic Pain from Blood Samples

Chronic pain is a widespread condition that remains difficult to manage, and existing clinical methods for its treatment rely largely on self-reporting, which can be subjective and especially problematic... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Sekisui Diagnostics UK Ltd.